NCT03932110

Brief Summary

In this study, the prevalence of metabolic syndrome in psoriatic and psoriatic arthritis patients as well as the parameters of metabolic syndrome will be examined. At the same time, the levels of omentin and visfatin adipokines associated with metabolic syndrome and obesity will be measured by measuring the disease severity (by PASI psoriasis, clinical activity score for psoriatic arthritis). The patients who accepted to participate in the study , who were admitted to the dermatology outpatient clinic were included in the study. For the blood tests required after the examination, 2 tubes of blood will be taken for the measurement of omentin and visfatin. 80 psoriasis, 40 psoriatic arthritis and 60 healthy volunteers were planned to be studied. AHA / NHLBI, 2005 (revised ATP III criteria) criterion for the diagnosis of metabolic syndrome will be used. Omentin and visfatin levels are compared with the severity of the disease for psoriasis and psoriatic arthritis, and it will be examined whether it is proinflammatory or antiinflammatory.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
180

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Apr 2019

Shorter than P25 for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 15, 2019

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

April 24, 2019

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 30, 2019

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2019

Completed
13 days until next milestone

Study Completion

Last participant's last visit for all outcomes

June 14, 2019

Completed
Last Updated

June 17, 2019

Status Verified

June 1, 2019

Enrollment Period

2 months

First QC Date

April 24, 2019

Last Update Submit

June 14, 2019

Conditions

Psoriasis VulgarisPsoriatic ArthritisMetabolic Syndrome

Keywords

psoriasis vulgarispsoriatic arthritismetabolic syndromeomentinvisfatin

Outcome Measures

Primary Outcomes (2)

  • omentin

    Omentin (omentin 1-2) is a specific protein that consists of amino acids released from vascular vessels

    6 months

  • visfatin

    Visfatin is an insulin-like protein that binds to insulin receptors produced mostly from visceral fatty tissue.

    6 months

Study Arms (3)

psoriasis vulgaris,

OTHER

patients who have only psoriasis vulgaris

Diagnostic Test: omentin, visfatin

psoriatic arthritis

OTHER

patients who have psoriatic arthritis

Diagnostic Test: omentin, visfatin

healthy control

OTHER

healthy people

Diagnostic Test: omentin, visfatin

Interventions

omentin, visfatinDIAGNOSTIC_TEST

diagnostic blood test

healthy controlpsoriasis vulgaris,psoriatic arthritis

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients followed up for psoriasis and psoriatic arthritis in dermatology and rheumatology clinic
  • Patients older than 18 years
  • Patients who accept dermatological and rheumatic examination
  • Patients not receiving systemic treatment related to the disease in the last 1 month

You may not qualify if:

  • Patients with autoimmune and rheumatic diseases other than psoriasis and psoriatic arthritis
  • Patients under 18 years
  • Patients who do not accept dermatological and rheumatic examination Patients receiving systemic therapy for the last 1 month pregnant and nursing moms

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Istanbul Medeniyet University, Department of dermatology

Istanbul, 34722, Turkey (Türkiye)

Location

Istanbul Medeniyet University

Istanbul, 34722, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Arthritis, PsoriaticMetabolic Syndrome

Condition Hierarchy (Ancestors)

SpondylarthropathiesSpondylarthritisSpondylitisSpinal DiseasesBone DiseasesMusculoskeletal DiseasesArthritisJoint DiseasesPsoriasisSkin Diseases, PapulosquamousSkin DiseasesSkin and Connective Tissue DiseasesInsulin ResistanceHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
M. D.

Study Record Dates

First Submitted

April 24, 2019

First Posted

April 30, 2019

Study Start

April 15, 2019

Primary Completion

June 1, 2019

Study Completion

June 14, 2019

Last Updated

June 17, 2019

Record last verified: 2019-06

Data Sharing

IPD Sharing
Will not share

Locations

TU(2)